| Zacks Company Profile for Urologix Inc. (ULGX : OTC) |
|
|
| |
| • Company Description |
| Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia, a condition that affects more than twenty three million men worldwide. Urologix' products include the CoolWave, Targis and Prostatron control units and the Cooled ThermoCath, Targis and Prostaprobe catheter families. Additionally, Urologix is currently developing CoolMax, its next generation microwave catheter for in-office benign prostatic hyperplasia treatment. All of Urologix' products utilize Cooled ThermoTherapy targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort and provide safe, effective, lasting relief of the symptoms of benign prostatic hyperplasia.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 36,746 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 0.46 |
| 52 Week High: $0.02 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Gregory J. Fluet - Chief Executive Officer; Interim Chief Financial O
Mitchell Dann - Director
Sidney W. Emery, Jr. - Director
Christopher R. Barys - Director
Patrick Spangler - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 917273104
SIC: 3845
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 0.46
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
